Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Glenmark Pharmaceuticals Ltd

| Quarterly Financial Results Q3 FY 2025-26

NEUTRAL SENTIMENT

Report Source

⬤30th Jan 26

Summary : Glenmark Pharmaceuticals reported mixed Q3 FY26 results, with standalone profit recovery but continued impact from significant legal settlements and restructuring costs.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Standalone Total expenses for Q3 FY26: Rs. 19,453.91 million.
  2. Consolidated Total expenses for Q3 FY26: Rs. 32,267.44 million.
  3. Exceptional items (gain)/loss for Q3 FY26 Standalone: Rs. 1,770.73 million (gain).
  4. Exceptional items (gain)/loss for Q3 FY26 Consolidated: Rs. 1,843.37 million (gain).
  5. Provision for US$ 37.75 million (Rs. 3,232.32 million) settlement charged as exceptional item in Q2 FY26.
  6. Provision for US$ 11 million (Rs. 976 million) settlement charged as exceptional item in Q2 FY26.
  7. Other exceptional items in Q2 FY26 included inventory provision (Rs. 5,901 million), receivables/other current assets (Rs. 4,885.16 million), and PP&E impairment (Rs. 2,153.46 million).
  8. Impact of new Labour Codes recognized as exceptional item in Q3 FY26: Rs. 1,778.91 million (consolidated) and Rs. 1,770.73 million (standalone).
  9. Provision on receivables and other current assets amounting to Rs. 4,885.16 million was an exceptional item in Q2 FY26.
  10. Standalone Net sales for Q3 FY26: Rs. 23,282.31 million.
  11. Consolidated Net sales for Q3 FY26: Rs. 38,879.99 million.
  12. Consolidated Total revenue for nine months ended 31st December 2025: Rs. 1,32,119.25 million.
  13. Multiple antitrust and consumer protection lawsuits in the U.S. which have led to settlements and provisions.
  14. Both standalone and consolidated results are presented.
  15. Consolidated revenue and expenses are significantly higher than standalone, reflecting global operations.

Corporate Overview

  1. Global presence with subsidiaries across Europe, UK, Mexico, Peru, Colombia, Uruguay, Venezuela, Egypt, UAE, Philippines, Nigeria, Malaysia, Australia, South Africa, Thailand, Germany, Canada, Kenya, Spain, Singapore, Austria.
  2. Significant legal challenges and settlements primarily in the Eastern District of Pennsylvania, U.S.
  3. Multiple antitrust and consumer protection lawsuits in the U.S. leading to significant settlements.
  4. Restructuring of IGI TSA innovation arm, including closure of manufacturing facility and project write-offs.
  5. Financial implications from new Indian Labour Codes.
  6. Pharmaceutical business focusing on generics and active pharmaceutical ingredient (API) components.
  7. Factual and compliant, reporting financial results and addressing legal/regulatory matters.
  8. Putative classes of direct purchasers, end payers, and indirect purchasers of generic drugs.
  9. One reportable segment: Pharmaceuticals.

Risk Factors

  1. Substantial legal settlement costs persist.
  2. Ongoing regulatory scrutiny in US.
  3. Financial impact of new Labour Codes.
  4. Dependence on generics and API markets.

Key Drivers

  1. Settling US antitrust lawsuits reduces uncertainty.
  2. Restructuring IGI TSA for efficiency.
  3. Standalone profit rebound after prior loss.
  4. Resolution of past legal and operational issues.

Auditor’s Report

  1. Unmodified review report for standalone and consolidated financial results.
  2. Reliance on review reports of other auditors for financial information of 39 subsidiaries, including 37 located outside India.

Board Commentary

  1. Antitrust and consumer protection lawsuits in the U.S.
  2. Financial impact of new Labour Codes.
  3. Multiple antitrust and consumer protection lawsuits in the U.S. leading to settlements.
  4. Financial implications arising from new Indian Labour Codes.
  5. Restructuring of IGI TSA, including closure of manufacturing facility at Le-Chaux-De-Fonds.

Corporate Governance

  1. Audit Committee reviewed the financial results.

Management Discussion & Analysis

Future Strategy

  1. Optimizing IGI TSA operations in line with long-term vision.
  2. Transferring CMC activities to Contract Development and Manufacturing Organization (CDMO) for continuity.

Operational Focus Areas

  1. Resolving ongoing legal disputes through settlements.
  2. Assessing and accounting for financial impact of new Labour Codes.

Risk Control Measures

  1. Entering into settlements to resolve antitrust lawsuits.
  2. Making provisions for estimated settlement amounts.
  3. Assessing financial implications of new Labour Codes on best estimate basis.

Critical Risks

  1. Exposure to significant legal and regulatory issues, particularly antitrust lawsuits in the U.S.
  2. Financial impact of restructuring activities and one-time costs.
  3. Uncertainty regarding the full impact of new Indian Labour Codes.
Glenmark Pharmaceuticals Ltd (GLENMARK) Quarterly Report Analysis & Insights | Dhanarthi